VINCERX PHARMA INC. - COMMON STOCK

Vincerx Pharma Reports Third Quarter 2024 Financial Results

12 Nov 2024 09:00:01 By Nasdaq GlobeNewswire

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

07 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2024 Financial Results

08 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

14 May 2024 16:15:00 By Nasdaq GlobeNewswire

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

26 Apr 2024 00:27:06 By Nasdaq GlobeNewswire

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

25 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

08 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

01 Apr 2024 08:00:01 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

29 Mar 2024 15:20:52 By Nasdaq GlobeNewswire

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 Mar 2024 16:31:00 By Nasdaq GlobeNewswire

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

07 Jan 2024 15:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

10 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma To Present Three Posters at ASH 2023 in December

02 Nov 2023 09:10:00 By Nasdaq GlobeNewswire

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

14 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Vincerx Pharma Announces FDA Clearance of IND for VIP943

22 Aug 2023 07:30:09 By Nasdaq GlobeNewswire

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 Aug 2023 09:25:00 By Nasdaq GlobeNewswire

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

19 Apr 2023 09:05:00 By Nasdaq GlobeNewswire